REGULATORY

• LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
  February 9, 2026

• MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
  February 9, 2026

• MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
  February 5, 2026

• Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
  February 4, 2026

• Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
  February 4, 2026

• MHLW Set to Launch Searchable Drug Supply Database in April
  February 3, 2026

• MHLW Pushes Back GCP Ordinance Revision to Summer
  February 3, 2026

• Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
  February 2, 2026

• Chuikyo Agrees to Apply Originator Optimal-Use Guidelines to Biosimilars
  February 2, 2026

• MHLW Panel Sets Safety Rules for Upcoming Pomalyst Generics
  February 2, 2026

• Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
  January 30, 2026

• MHLW to Ease Uniform Driving Restrictions on Oral Antiepileptics
  January 29, 2026

• MHLW Eyes Distribution Rules in Revamped Supply Support Premium: Chuikyo
  January 29, 2026

• Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
  January 29, 2026

• Japan’s Lower House Campaign Begins amid Fragmented Political Set-Up
  January 28, 2026

• Former LDP Lawmakers Outline Drug Policy Priorities in Comeback Bids
  January 28, 2026

• Health Minister Ueno Vows to Tackle Drug Loss through Innovation Push: Snap Poll
  January 28, 2026

• Ex-MHLW Official Toyota Seeks Political Comeback on Sanseito Ticket
  January 28, 2026

• Chuikyo OKs Health Coverage for Optune Lua, CDx for Inluriyo and Elevidys
  January 26, 2026

• Japan to Bolster Reimbursement Incentives for Biosimilars in FY2026 Fee Revision
  January 26, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »